Maynard Um
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) Misses Q3 EPS by 113c
-
-
-
-
-
-
-
Jasper Therapeutics cuts workforce by 50% to extend cash runway
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) PT Lowered to $20 at BTIG
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Jasper Therapeutics (JSPR)
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) PT Lowered to $64 at BTIG
-
-
-
-
-
-
-
Jasper Therapeutics (JSPR) Falls 40% Following Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Jasper Therapeutics (JSPR)
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

